Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis

Journal of the American Academy of Dermatology

Volumn 60, Issue 6, 2009, Pages 1032-1036

  Cheung, Dianne ^a   Bryer Ash, Michael ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

cytokine; HbA1c; insulin; insulin resistance; TNF receptor

Indexed keywords

ETANERCEPT; GLIPIZIDE; INSULIN; ISOPHANE INSULIN; REPAGLINIDE; ROSIGLITAZONE;

AGED; ANAMNESIS; BEDTIME DOSAGE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DRUG DOSE INCREASE; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LABORATORY TEST; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PSORIASIS VULGARIS; REVIEW;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; IMMUNOGLOBULIN G; INSULIN RESISTANCE; MALE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 67349160559     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.12.012     Document Type: Review

References (22)

1. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 363 (2004) 675-681
2. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., and Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356 (2000) 385-390
3. Brandt J., Khariouzov A., Listing J., Haibel H., Sorensen H., Grassnickel L., et al. Six-month results of a double-blind placebo-controlled trail of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48 (2003) 1667-1675
4. Gottlieb A.B., Leonardi C.L., Goffe B.S., Ortonne J.P., van der Kerkhof P.C., Zitnik R., et al. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 54 Suppl (2006) S92-100
5. Rapp S.R., Feldman S.R., Exum M.L., Fleischer Jr. A.B., and Reboussin D.M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41 (1999) 401-407
6. Christophers E. Comorbidities in psoriasis. Clin Dermatol 25 (2007) 529-534
7. Bonilla E., Lee Y.Y., Philips P.E., and Perl A. Hypoglycemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus. Ann Rheum Dis 66 (2007) 1688
8. Yazdani-Biuki B., Mueller T., Brezinscheck H.P., Hermann J., Graninger W., and Wascher T.C. Relapse of diabetes after interruption of chronic administration of anti-TNF-alpha antibody infliximab. Diabetes Care 29 (2006) 1712-1713
9. Cohen A.D., Dreiher J., Shapiro Y., Vidavsky L., Vardy V.A., Davidovici B., et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 22 (2008) 585-589
10. Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B., and Gelfand J.M. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55 (2006) 829-835
11. Mallbris L., Ritchlin C.T., and Stahle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 8 (2006) 355-363
12. Sommer D.M., Jenisch S., Suchan M., Christophers E., and Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298 (2006) 321-328
13. Henseler T., and Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 32 (1995) 982-986
14. Boulton J.G., and Bourne J.T. Unstable diabetes in patient receiving anti-TNF-α for rheumatoid arthritis. Rheumatology (Oxford) 46 (2007) 178-179
15. Marra M., Campanati A., Testa R., Sirolla C., Bonfigli A.R., Fraceschi C., et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol 20 (2007) 731-736
16. Melloul D. Role of NF-κB in β-cell death. Biochem Soc Trans 36 (2008) 334-339
17. Mandrup-Poulsen T. Apoptotic signal transduction pathways in diabetes. Biochem Pharmacol 66 (2003) 1433-1440
18. Uysal K.T., Wiesbrock S.M., Marino M.W., and Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 389 (1997) 610-614
19. Jellema A., Plat J., and Mensink R.P. Weight reduction, but not a moderate intake of fish oil, lowers concentrations of inflammatory markers and PAI-1 antigen in obese men during the fasting and postprandial state. Eur J Clin Invest 34 (2004) 766-773
20. Martínez-Abundis E., Reynoso-von Drateln C., Hernández-Salazar E., and González-Ortiz M. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res 299 (2007) 461-465
21. Dominguez H., Storgaard H., Rask-Madsen C., Steffen Hermann T., Ihlemann N., Baunbjerg Nielsen D., et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 42 (2005) 517-525
22. Cryer P.E. Diverse causes of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 250 (2004) 2272-2279